The pharmaceutical side of psychedelics
Following strict scientific standards to protect patients and help produce reliable clinical trials results
Alejandro Antalich
Chief Executive Officer & Director
Mr. Antalich is the former Chief Executive Officer of the Canadian Company ICC Labs Inc. (TSXV), the first publicly traded company in the world to sell cannabis to a federal government, bridging the gap between the stigma behind certain controlled substances and regulators. Through strategic foresight, determination, commitment, responsibility, teamwork and passion, he led ICC Labs to its successful sale to Aurora (TSX) in November 2018, one of the largest participants in the industry, a $300 million transaction. An entrepreneur and investor with a commercial instinct and vision towards business growth, operations, manufacturing and product development. A savvy negotiator that manages unique relationship building skills.
Oscar León
Chief Financial Officer & Director
A highly experienced Certified Public Accountant with a solid background in Financial Management, Accounting, Project Finance and Risk Analysis, with experience in Agriculture, Cannabis, Mining and Hydropower Industries. US/Canadian GAAP, IFRS knowledge, SEC and TSX reporting and filing experience. Strong sense of teamwork, quality and ethics. A results-oriented individual who demonstrates his abilities to the benefit of the organization. 3+ decades of experience as Certified Public Accountant. 2+ decades of experience as CFO, Financial Controller, Chief Accountant for several Uruguayan, Canadian and American Companies.
Juan Presa
Chief Legal Officer
Attorney at law from the Catholic University in Uruguay, specializing in corporate, commercial and international law. Juan has worked with companies from diverse industries such as agriculture, mining, cannabis, FinTech, including listed companies both on the New York Stock Exchange and the Toronto Stock Exchange. Juan developed the business expansion of companies through South America, Asia-Pacific and Africa, and participating in mergers and acquisitions of both public and private companies, public offerings and private placement financings.
Paola Díaz Dellavalle
Chief Scientific Officer
Ms. Díaz Dellavalle has a Ph.D in chemistry and natural molecules with more than 15 years of experience in research, development, and management in biotechnology projects. She has studies in intellectual property and competitive intelligence analysis, with vast experience in patent strategy and technology transfer, specializing in the fields of chemistry, life sciences, pharmacy and biotechnology. During her career, she has led teams of scientists and managed subcontractors for non-clinical studies and new molecule development programs.